> 4.5 and 5.2). The c oncomi tant use of  ZE PATIER  and strong CYP3A  inhibitors increases ELBASVIR and grazoprevirconcentrations
, and co -administration  is not recommended
 (see section  4.5). HCV/HBV (hepatitis B virus) c o-inf ection
> Potential f or other  medicinal  products to af f ect ZEPATIERGrazoprevir is  a substrate of OATP1 B drug tran sporters. Co -administration of  ZEPATIER withmedicinal products that inhibit OATP1B transporters is contraindicated because it
 may resul t in asignificant increase in the  plasma concentration of  GRAZOPREVIR ( see sections 4.3 and 4.4).ELBASVIR and grazopr evir are substr ates of  CYP3A  and P-gp. Co -admi nistration of inducers of  CYP
3Aor P-gp with ZEPATIER  is contraindicated because
 it may de creas e ELBASVIR and grazoprev ir plasmaconcentrations, which may lead to  reduce d therape utic ef f ect of ZEPATI ER (see sec tions 4.3 and 4 .4). Co-administration of  ZEPATIER  with strong CYP3A inhibitors inc reases ELBASVIR and grazop revirplasma con centration s, and co-administration is
 not recommended  (see Table  2 and sect ion 4.4).6Co-administra tion of  ZEP ATIER with P-gp inhib itors is expected to have a minimal eff ect on theplasma concentrations of ZEPATIER.The potential f or GRAZOPREVIR to be a breast cance r resistance protein ( BCRP ) substr ate cannot  beexcluded.Potent ial f or  ZEPATI ER to af f ect other m edicinal products
> ELBASVIR and GRAZOPREVIR are inh ibitors of the drug transpo rter BCRP  at the i ntestinal  level in humansand may increase plasma concentrati ons o f co-administered BCRP substr ates. ELBASVIR is not a
> CYP3A i nhibito r in vitro and g razop revir is a weak CYP3 A inhib itor in humans.
 Co-administrat ionwith GRAZOPREVIR did not result in clinically rele vant increases in exposures of  CYP3A substrates.Theref or e, no dose adjustment is
 required f or CYP3A substrates when co-admi nistered with
> ZEPATIE R. ELBASVIR has minimal i ntestinal P -gp inhibition in humans, and does not result in clinically relevantincreases in concentrations of
 DIGOXIN (a P
-gp substrate ), with an 11% increase in plasma AUC.GRAZOPREVIR is not a P
-gp inhibit or based on in vitro data. ELBASVIR and grazopre vir are not OATP1Binhibitors in humans. Based
 on in vitro data, clinically
 signif ic ant interactions with ZEPATIER as aninhib itor of  ot her C YP ENZYMES, UGT1A1, esterases  (CES1, CES2, and Cat
> Interact ion not studied. Expected:  
↑ Dabiga tran(P-gp inhibition)Concentrations of  DABIGATRAN mayincrease wh en co -admini stered withelbasvir
, with possible increased bleedingrisk. Clini cal and laboratory  monito ring isrecommended. Vitamin Kantagonists
> Interaction not studied. Close monito ring of  INR  is recommendedwith all VITAMIN K ANTAGONISTS
. This is dueto liver f unction changes during treatmentwith ZEPATIER.ANTICONVULSANTSCarbamazepine  PHENYTOIN  Interaction not studied. Expected: 
↓ ELBASVIR
↓ GRAZOPREVIR(CYP3A or P -gp induction)Co-administration is contraindicated.8Medicin alproduct bytherapeuticareas Effects on medi cinal product levels. Mean ratio (90
 
% confidence
 interv al)for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIERANTIFUNGALSKetoconazole(400 mg PO oncedaily)/ ELBASVIR(50 mg single dose)
↔ ELBASVIR
> AUC 1.80 (1.41, 2.29)Cmax 
1.29 (1.00, 1.66) C24 1.89 (1.37, 2.60)Co-administration is not recommended.(400 mg PO oncedaily)/ GRAZOPREVIR(100 mg singledose)↑ GRAZOPREVIR
> AUC 1.22 (1.06, 1.40)Cmax 
1.41 (1.18, 1.68) C24 
1.31 (1.12, 1.53) Co-administration is contraindicated.(600 mg IV single dose)/ GRAZOPREVIR (200 mg single dose) 
> AUC 1.11 (1.01, 1.20)Cmax 
0.92 (0.81, 1.06) C24 1.39 (1.25, 1.56)No dose adjustment is required
.ENDOTHELIN ANTAGONISTBosentan  Interaction not studied. Expected: 
↓ ELBASVIR
↓ Grazop revir(CYP3A or P -gp induction)Co-administration is contraindicated.9Medicin al product by therapeutic areas  Effects on medi cinal product levels. Mean ratio (90
 
% confidence
 interv al)for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIERHCV ANTIVIRAL AGENTSSof osbuvir  (400 mg single dose sof osbuvir)/ ELBASVIR (50 mg once daily)/GRAZOPREVIR(200 mg once daily↔ SOFOSBUVIR
> AUC 2.4 3 (2.12, 2. 79)Cmax 
2.27 (1.72, 2.99) 
↔ GS -331007AUC 1.13 (1.05, 1.21)Cmax 
0.87 (0.78, 0.96) C24 1.53 (1.43, 1.63)No dose adjustment is required. HERBAL SUPPLEMENTSSt. John’s wort (Hypericum perforatum ) Interaction not studied. Expected: 
↓ Elba svir
↓ Graz oprevi r(CYP3A or P -gp ind uction)Co-administration is contraindicated.HBV AND HIV ANTIVIRAL AGENTS: NUCLEOS(T)IDE REVERSE TRANSCRIPTASEINHIBITORSTenof ovir disoproxil f umarate(300 mg once daily)/ ELBASVIR (50 mg once daily)  ↔ ELBASVIR
> ↑ ELBASVIR  AUC 4.76 (4.07, 5.56)Cmax 
4.15 (3.46, 4.97) C24 6.45 (5.51, 7.54)(combination of  mechanisms including
> AUC 1.07 (0.98, 1.17) Cmax 
1.02 (0.96, 1.08) C24 1.15 (1.02, 1.29)Co-administration is contraindicated.(300 mg oncedaily)/ RITONAVIR(100 mg once daily/GRAZOPREVIR(200 mg oncedaily)↑ GRAZOPREVIR  AUC 10.58 (7.78, 14.39) Cmax 6.24 (4.42, 8. 81) C24 
11.64 (7.96, 17.02
)(combination of  OATP1B and CYP3Ainhibition)
↔ ATAZANAVIR
> AUC 0.95 (0.86, 1.06)
 Cmax 
0.95 (0.85, 1.05) C12 0.94 (0.85, 1.05)Co-administration is contraindicated.(600 mg twicedaily)/ RITONAVIR(100 mg twicedaily/ GRAZOPREVIR(200 mg on cedaily)↑ GRAZOPREVIR  AUC 7.50 (5.92, 9.51)Cmax 5.27 (4.04, 6.86)C24 
8.05 (6.33, 10.24)
  (combination of  OATP1B and CYP3Ainhibition)
↔ DARUNAVIR
> AUC 1.02 ( 0.93, 1.13)Cmax 1.02 (0.92 , 1.13) C12 1.07 (0.97, 1.18)Co-administration is contraindicated.(400 mg twicedaily)/ RITONAVIR(100 mg twicedaily/ GRAZOPREVIR(200 mg oncedaily)↑ GRAZOPREVIR  AUC 12.86 (10.25, 16.13)Cmax 7.31 (5.65, 9.45)  C24 21.70 (12.99, 36.25)(combinatio n of  OATP1B and CYP3Ainhibition)
↔ LOPINAVIR
> CYP3A inhibition)Co-administration is contraindicated.12Medicin al product by therapeutic areas  Effects on medi cinal product levels.  Mean ratio (90
 
% confidence
 interv al) for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIERHIV ANTIVIRAL AGENTS: NON
-NUCLEOSIDE HIV REVERSE TRANSCRIPTASEINHIBITORSEf avirenz(600 mg once daily)/ ELBASVIR (50 mg once daily)  ↓ ELBASVIR  AUC 0.46 (0 .36, 0.59)Cmax 
0.55 (0.41, 0.73) C24 0.41 (0.28, 0.59)(CYP3A or P -gp induction)
↔ EFAVIRENZ
> AUC 0.82 (0.78, 0.86)Cmax 
0.74 (0.67, 0.82) C24 0.91 (0.87, 0.96)Co-administration is contraindicated.(600 mg oncedaily)/ GRAZOPREVIR(200 mg oncedaily)↓Grazoprev ir
> Interaction not studied. Expected: 
↓ ELBASVIR
↓ Gra zoprevir(CYP3A or P -gp induction)Co-administration is contraindicated.RILPIVIRINE(25 mg once daily)/ELBASVIR (50  mgonce daily)/GRAZOPREVIR(200 mg oncedaily) ↔ ELBASVIR
> AUC 1.43 (0.8 9, 2.30)Cmax 
1.46 (0.78, 2.73) C12 1.47 (1.08, 2.00)14Medicin al product by therapeutic areas  Effects on medi cinal product levels.  Mean ratio (90
 
% confidence
 interv al) for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIERHIV ANTIVIRAL AGENTS: OTHERElvitegravir/COBICISTAT/EMTRICITABINE/tenof ovir disoproxil f umarate (f ixed
-dose combination)ELVITEGRAVIR (150 mg once daily)/cobi cistat (150 mg once daily)/ emtricitabi ne (200 mg once daily)/ tenof ovir disoproxil f umarate (300 mg once daily)/ELBASVIR (50 mg once daily)/ GRAZOPREVIR (100 mg once daily) 
> AUC 1.07 (1.03, 1.10)Cmax 
0.96 (0.90, 1.02) C24 
1.19 (1.13, 1.25) 
↔ TENOFOVIR AUC 1.18 (1.13, 1.24)Cmax 1.25 (1.14, 1.3 7) C24 1.20 (1.15, 1.26)Co-administration with ZEPATIER iscontraindicated.HMG -Co
> AUC 0.96 (0.90, 1.02)Cmax 
0.90 (0.85, 0.97) C12 
1.00 (0.92, 1.08) Co-administration is contraindicated.Mycophenolatemof etil(1,000  mg singledose)/ ELBASVIR(50 mg once daily)/GRAZOPREVIR(200 mg oncedaily) ↔ ELBASVIR
> AUC 1.43 (1.24, 1.64)Cmax 
0.60 (0.52, 0.69) C12 1.70 (1.49 , 1.94) (CYP3A inhibition)Frequent monitoring of  TACROLIMUS wholeblood concentrations, changes in renalf unction, and TACROLIMUS
-associatedadverse events upon the initiation of  co
-administration is recommended.
 Closemonitoring and potential dose adju stmentof  TACROLIMUS may be required duringtherapy, as TACROLIMUS levels may decreaserelated to clearance of  HCV.KINASE INHIBITORSunitinib  Interaction not studied. Expected: 
↑ SUNITINIB(possibly due to intestinal BCRP inhibition)Co-administration of  ZEPATIER withsunitinib may increase sunitinibconcentrations leading to an increased riskof  SUNITINIB -associated adverse events.Use with caution; dose adjustment ofsunitinib  may be required.18Medicin al product by therapeutic areas  Effects on medi cinal product levels. Mean ratio (90
 
% confidence
 interv al)for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIEROPIOID -SUBSTITUTION THERAPYBuprenorphine/NALOXONE(8 mg/2  mg single dose)/ ELBASVIR (50 mg single dose)
 ↔ ELBASVIR
> Interaction not studied. Expe cted: 
↓ ELBASVIR
↓ GRAZOPREVIR(CYP3A or P -gp induction)Co-administration is contraindicated.Paediatric population
